ArticleKidney3602026
Cross-Species Comparison between Mouse Kidney Multi-Omics and Human Genome-Wide Association Studies Highlights Molecular Features Associated with Oxalate Nephropathy.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
key pointsThe cross-species integration of mouse kidney multi-omics and human genome-wide association study identified 46 cross-species urolithiasis-related molecules. Cell type enrichment suggested that immune cells and collecting duct principal cells may play roles in urolithiasis pathophysiology. Follow-up analyses using human renal data, colocalization, and Mendelian randomization supported the relevance of the detected 46 molecules in humans.
backgroundUrolithiasis, a recurrent and increasingly prevalent disease worldwide, has a complex pathophysiology that hinders a comprehensive understanding.
methodsWe performed a cross-species integrative analysis combining multi-omics profiling of kidneys from a hyperoxaluric mouse model and summary statistics from a large-scale human genome-wide association study (GWAS).
resultsIn the multi-omics analysis of kidneys from a hyperoxaluric mouse model using RNA-seq, whole-cell proteomics, and phosphoproteomics, we identified 1173 genes, 342 proteins, and 516 phosphorylated peptides that were differentially expressed compared with control mice. We used publicly available large-scale meta-GWAS summary statistics of urolithiasis from BioBank Japan, UK Biobank, and FinnGen ( n =198,769) and prioritized genes using gene enrichment analysis. Through cross-species integration of mouse and human omics, we identified 46 molecules potentially relevant to urolithiasis, hereafter referred to as cross-species urolithiasis-related molecules. We examined the expression and genetic associations of these 46 molecules in human urolithiasis. Among these, CRYAB and SHROOM3 showed differential expression in human renal papilla tissues with and without stones. Colocalization analysis between urolithiasis GWAS and expression quantitative trait loci data of human renal tubules and glomeruli suggested shared signals at the GLUD1 , UMOD , SLC34A1 , TCEA3 , and H1-0 regions. Mendelian randomization analysis using the same renal expression quantitative trait loci datasets further supported these findings, with GLUD1 , UMOD , TCEA3 , and H1-0 showing statistically significant associations, suggesting a strong genetic link with urolithiasis.
conclusionsThe study's findings highlight a set of cross-species urolithiasis-related molecules, supported by both expression and genetic evidence, offering insights for future functional validation and mechanistic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.